Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NEK7 | Q8TDX7 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13284939 | 0.86 | ALDH1A1 (0.51) | ALDH1A1LMNAMAPK14SMN1; SMN2NEK7 | |
| SCHEMBL9893106 | 0.84 | ALDH1A1 (0.57) | ALDH1A1LMNAMAPK14SMN1; SMN2NEK7 | |
| SCHEMBL9891811 | 0.83 | ALDH1A1 (0.64) | ALDH1A1LMNAMAPK14SMN1; SMN2RAB9A | |
| SCHEMBL13015651 | 0.82 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPK14SMN1; SMN2NEK7 | |
| SCHEMBL23966930 | 0.76 | ALDH1A1 (0.46) | ALDH1A1LMNASMN1; SMN2RAB9AMAPT | |
| SCHEMBL2678545 | 0.76 | ALDH1A1 (0.45) | ALDH1A1LMNAMAPK14SMN1; SMN2NEK7 | |
| SCHEMBL9891802 | 0.75 | MAPK14 (0.48) | ALDH1A1LMNAMAPK14SMN1; SMN2RAB9A | |
| SCHEMBL15000477 | 0.75 | ALDH1A1 (0.60) | ALDH1A1LMNASMN1; SMN2RAB9AADORA2B | |
| SCHEMBL27605122 | 0.74 | CYP1A2 (0.54) | ALDH1A1LMNASMN1; SMN2RAB9AMAPT | |
| SCHEMBL13413822 | 0.73 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPK14RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 3279/4885LMNA 4696/4885MAPK14 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.